In a 60-year-old woman with recent antibiotic treatment for a urinary tract infection, on methotrexate for rheumatoid arthritis and warfarin for atrial fibrillation, presenting with a week of increasing watery non‑bloody diarrhea, lower abdominal cramping, mild diffuse tenderness, anemia, leukocytosis, impaired renal function, and elevated C‑reactive protein, which diagnosis is most likely: ischemic colitis, inflammatory bowel disease, microscopic colitis, or Clostridioides difficile colitis?

Most Likely Diagnosis: Clostridioides difficile Colitis

The most likely diagnosis in this 60-year-old woman is Clostridioides difficile colitis (Option D), given her recent antibiotic exposure for UTI, watery non-bloody diarrhea increasing to 6 episodes daily, leukocytosis (WBC 13,000), elevated inflammatory markers (CRP 4), and acute kidney injury (creatinine 1.5). 1

Clinical Reasoning

Why C. difficile is Most Likely

The clinical presentation strongly points toward C. difficile infection based on several key features:

Recent antibiotic exposure is the single most important risk factor for CDI 1. The guidelines explicitly state that antibiotic use is the most critical predisposing factor, as antibiotics disrupt normal gut flora, allowing C. difficile to proliferate and produce toxins 1.

Additional risk factors present:

• Age >60 years (established risk factor) 2
• Immunosuppression from methotrexate for rheumatoid arthritis 2, 3
• Proton pump inhibitor use (apixaban mentioned, but PPIs are common in this population) 2

Clinical features consistent with CDI:

• Watery, non-bloody diarrhea (classic presentation) 1
• Leukocytosis (WBC 13,000) - the guidelines note that marked leukocytosis >15×10⁹/L indicates severe colitis, but this patient's WBC of 13,000 is consistent with non-severe CDI 1
• Elevated CRP indicating systemic inflammation 1
• Rise in creatinine (1.5) suggesting volume depletion from diarrhea and potential early organ dysfunction 1
• Lower abdominal cramping and tenderness (typical of CDI) 1

Why Other Diagnoses Are Less Likely

Ischemic colitis (Option A):

• Typically presents with bloody diarrhea or hematochezia, not watery non-bloody stools 4
• More common in watershed areas (splenic flexure, rectosigmoid junction)
• Usually associated with sudden onset severe abdominal pain
• The absence of blood makes this diagnosis unlikely

Inflammatory bowel disease (Option B):

• New-onset IBD at age 60 is less common (though not impossible)
• Would typically show bloody diarrhea in ulcerative colitis
• No prior history mentioned
• The temporal relationship with recent antibiotics strongly favors CDI over new IBD
• However, IBD patients can have concurrent CDI 5

Microscopic colitis (Option C):

• Presents with chronic watery diarrhea (consistent feature) 6
• More common in older females (fits demographics)
• Associated with NSAIDs, PPIs, and immune-mediated diseases 6
• However, the acute presentation (one week duration) with recent antibiotic exposure makes CDI far more likely
• Microscopic colitis typically has a more insidious, chronic course
• The leukocytosis and elevated CRP are less typical of microscopic colitis

Severity Assessment

This patient has non-severe CDI based on ESCMID criteria 1:

• Stool frequency 6 times daily (mild CDI defined as <4 times daily, but this doesn't meet severe criteria)
• No fever (severe colitis includes fever >38.5°C)
• No hemodynamic instability
• WBC 13,000 (severe defined as >15×10⁹/L) 1
• Mild abdominal tenderness without peritoneal signs
• Creatinine 1.5 represents <50% rise from unknown baseline (severe defined as >50% rise) 1

However, the patient has concerning features requiring close monitoring:

• Leukocytosis approaching severe threshold
• Acute kidney injury (volume depletion vs. early severe disease)
• Immunosuppression from methotrexate 3

Diagnostic Approach

Immediate testing required:

• Stool testing for C. difficile toxin (nucleic acid amplification test/PCR preferred, or toxin EIA) 7, 8
• Only test diarrheal stool - testing should only be performed in symptomatic patients 7
• Do not perform "test of cure" as patients can shed spores asymptomatically for weeks 7

Important caveat: The diagnosis requires both clinical symptoms AND positive stool test for toxigenic C. difficile 1, 7. However, given the high pretest probability, empiric treatment may be considered while awaiting results if the patient deteriorates.

Management Recommendations

Immediate actions:

1. Discontinue the antibiotic used for UTI treatment (if still ongoing) 1, 2
2. Avoid antiperistaltic agents and opiates (contraindicated in CDI) 1
3. Implement contact precautions and isolate patient 2
4. Aggressive fluid resuscitation and electrolyte replacement 9

Antibiotic treatment for non-severe CDI 1:

• First-line: Oral metronidazole 500 mg three times daily for 10 days (for non-severe disease) 1
• Alternative: Oral vancomycin 125 mg four times daily for 10 days (if metronidazole contraindicated or for severe disease) 1
• Oral fidaxomicin 200 mg twice daily for 10 days (alternative, lower recurrence rates but more expensive) 9, 7

Monitor closely for progression to severe disease:

• Daily assessment of stool frequency, vital signs, abdominal exam
• Serial WBC, creatinine, lactate if worsening 1
• Escalate to vancomycin if no improvement in 3 days or if deterioration occurs 1

Special considerations in this patient:

• Methotrexate increases infection risk and may complicate CDI 3
• Consider holding methotrexate temporarily during acute CDI treatment
• Warfarin requires monitoring as metronidazole can potentiate anticoagulation
• The anemia (Hgb 10) may be pre-existing from chronic disease or methotrexate, but monitor for GI bleeding

Common Pitfalls to Avoid

1. Do not attribute diarrhea to methotrexate alone - while methotrexate can cause GI toxicity 3, the recent antibiotic exposure makes CDI the primary concern
2. Do not delay testing or treatment - CDI can rapidly progress to fulminant colitis with high mortality 1
3. Do not use loperamide or other antidiarrheals - these are contraindicated and may precipitate toxic megacolon 1
4. Do not test for C. difficile after symptom resolution - asymptomatic carriage is common and does not require treatment 7
5. Do not assume negative initial testing rules out CDI - enzyme immunoassays have high false-negative rates; repeat testing or use PCR if clinical suspicion remains high 7, 8